The Rastetter Family Trust, affiliated with a director of Dare Bioscience, Inc., filed a Form 144 notice of proposed sale of 859 shares of common stock on November 19, 2026.
Key Highlights
- Seller: The Rastetter Family Trust, with William H. Rastetter signing as trustee, holds a director relationship to the issuer.
- Shares proposed for sale: 859 shares of Dare Bioscience common stock, with an aggregate market value of $382.26 according to the filing.
- Approximate sale date: November 19, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
- Shares outstanding: The filing states 19,669,000 shares of common stock outstanding.
- Acquisition history: The shares were acquired through a combination of board compensation and various pre-IPO private investments in Cerulean, with acquisition dates ranging from May 8, 2007 to January 3, 2017.
- Prior three-month sales: The filing reports nothing to report under securities sold during the past three months.
Rastetter Family Trust Proposes Sale of Dare Bioscience Common Stock
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission on November 19, 2026, the Rastetter Family Trust has provided notice of a proposed sale of 859 shares of common stock in Dare Bioscience, Inc. (NASDAQ:DARE). The trust is identified as having a director relationship to the issuer, and William H. Rastetter signed the form as trustee. The aggregate market value of the shares proposed to be sold is listed as $382.26 in the filing.
The filing discloses that the shares were acquired across multiple transactions spanning approximately a decade. Several lots were obtained through board compensation from the issuer, with acquisition dates listed as October 1, 2016, October 3, 2016, and January 3, 2017, totaling 361 shares from those transactions. The remaining shares are described as derived from various pre-IPO private investments in Cerulean, with cash purchases recorded on dates between May 8, 2007 and April 15, 2014, as well as one lot of 157 shares acquired through the IPO on April 17, 2014. The filing identifies the issuer as the named person from whom the securities were acquired in each case.
The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services in New York. The filing reports no sales of Dare Bioscience securities by the trust during the three months preceding this notice. As of the filing date, Dare Bioscience, Inc. is located at 3655 Nobel Drive, Suite 260, San Diego, California 92122, and the company's SEC file number is listed as 001-36395.
What Was Disclosed
The Rastetter Family Trust filed a Form 144 notice on November 19, 2026, disclosing a proposed sale of 859 shares of Dare Bioscience common stock with an aggregate market value of $382.26, acquired through board compensation and pre-IPO cash investments dating to 2007.



Please wait processing your request...